EPH Receptor A2 anticorps (Extracellular, N-Term)

N° du produit ABIN7043122

Cet anticorps Lapin Polyclonal détecte spécifiquement EPH Receptor A2 dans WB, IHC, FACS et LCI. Il présente une réactivité avec des échantillons de Humain.

Aperçu rapide pour EPH Receptor A2 anticorps (Extracellular, N-Term) (ABIN7043122)

Antigène: EPH Receptor A2 (EPHA2)

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp EPH Receptor A2 est non-conjugé

Application: Western Blotting (WB), Immunohistochemistry (IHC), Flow Cytometry (FACS), Live Cell Imaging (LCI)

Détail du produit anti-EPH Receptor A2 anticorps

Épitope: AA 333-347, Extracellular, N-Term

Fonction: A Rabbit Polyclonal Antibody to EphA2 Receptor

Réactivité croisée: Humain, Souris, Rat

Homologie: Rat - 14,15 amino acid residues identical, mouse - 13

Attributs du produit: Anti-EphA2 (extracellular) Antibody (ABIN7043122, ABIN7044249 and ABIN7044250) is a highly specific antibody directed against an epitope of human EPHA2. The antibody can be used in western blot and live cell flow cytometry applications. It has been designed to recognize EphA2 from rat, mouse, and human samples.

Purification: Affinity purified on immobilized antigen.

Immunogène: (C)HYLTAVGMGAKVELR, corresponding to amino acid residues 333 - 347 of human EphA2

Isotype: IgG

Information d'application

Indications d'application:

WB: 1:200

FC: 2.5 μg per reaction

ICC: The optimal concentration should be determined by the user

IHC: 1:300

IP: The optimal concentration should be determined by the user

Commentaires:

Negative Control: (ABIN7235278)

Blocking Peptide: (ABIN7235278)

Restrictions: For Research Use only

Stockage

Format: Lyophilized

Reconstitution: 25 μL, 50 μL or 0.2 mL double distilled water (DDW), depending on the sample size.

Concentration: 0.8 mg/mL

Buffer: PBS pH 7.4, 1 % BSA with 0.05 % sodium azide

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: -20 °C

Stockage commentaire: The antibody ships as a lyophilized powder at room temperature. Upon arrival, it should be stored at -20°C

Détails sur EPH Receptor A2

Antigène: EPH Receptor A2 (EPHA2)

Autre désignation: EPHA2

Sujet:

Synonyms: Ephrin type A receptor 2, EPH Receptor A2, Epithelial Cell Kinase, Tyrosine-Protein Kinase Receptor ECK, ECK, EPHA2

Description: Erythropoietin-producing hepatocellular receptor A2 (EphA2) is a tyrosine kinase that belongs to the Ephrin (Eph) family of receptors. Members bind to cell surface-associated Ephrin ligands on neighboring cells. This binding generates bidirectional signaling which is a major form of contact-dependent communication between cells1. Eph receptors are divided into two classes, EphA and EphB, depending on the homology of their extracellular domains. Each extracellular domain is composed of a ligand-binding domain, Sushi domain, epidermal growth factor (EGF)-like domain, and two fibronectin type-III repeats. Eph receptors also contain a transmembrane domain, juxtamembrane region, tyrosine kinase domain, sterile alpha motif (SAM) and postsynaptic density (PSD)-95 protein, Discs large, and Zona occludens tight junction protein (PDZ) domain-binding motif.The interaction between Ephrin and the Eph receptor results in both "forward signaling" and "reverse signaling," which are mediated by Eph receptor and Ephrin, respectively2. Forward signaling induces Eph receptor oligomer clustering, cross-phosphorylation of tyrosine residues on the juxtamembrane domain and activation loop and, consequently, activation of the kinase activity.Eph receptor-ligand interactions mainly regulate cell proliferation and migration during development as well as tissue homeostasis, axon guidance, synapse plasticity, tissue remodeling, bone morphogenesis, and angiogenesis2.EphA2 is expressed in normal epidermal cells and in various solid tumors, such as breast, ovary, prostate, pancreas, glioblastoma, neck, renal, lung, melanoma, bladder and other types of cancer2.EphA2 expression in tumors is associated with a more aggressive cancer phenotype and correlates with tumor metastasis and poor patient outcome. In contrast, EphA2 also reduces cancer cell motility and proliferation and hence has both pro- and anti-oncogenic roles, depending on the cellular context3.Due to its pivotal role in various diseases, EphA2 is an appealing drug target and research is performed in order to control its activity4.

ID gène: 1969

NCBI Accession: NM_004431

UniProt: P29317

Pathways: Signalisation RTK